Articles producció científica> Medicina i Cirurgia

New perspectives on CKD-induced dyslipidemia

  • Datos identificativos

    Identificador: imarina:5251825
    Autores:
    Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J.
    Resumen:
    Introduction: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
  • Otros:

    Autor según el artículo: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J.
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Masana Marín, Luis
    Palabras clave: Type-2 diabetes-mellitus Subclinical atheromatosis Risk-factors Peritoneal-dialysis Lipoproteins Lipid abnormalities High-density-lipoprotein Hemodialysis-patients Dyslipidemia Chronic-renal-failure Chronic kidney-disease Chronic kidney disease Cardiovascular-disease Cardiovascular disease Atherosclerosis dyslipidemia chronic kidney disease cardiovascular disease atherosclerosis
    Resumen: Introduction: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
    Áreas temáticas: Pharmacology & pharmacy Pharmacology Molecular medicine Medicina ii Medicina i Interdisciplinar Farmacia Ensino Drug discovery Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciência de alimentos
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 14728222
    Direcció de correo del autor: luis.masana@urv.cat
    Identificador del autor: 0000-0002-0789-4954
    Fecha de alta del registro: 2024-09-07
    Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
    Enlace a la fuente original: https://www.tandfonline.com/doi/abs/10.1080/14728222.2017.1369961?journalCode=iett20
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Expert Opinion On Therapeutic Targets. 21 (10): 967-976
    Referencia de l'ítem segons les normes APA: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J. (2017). New perspectives on CKD-induced dyslipidemia. Expert Opinion On Therapeutic Targets, 21(10), 967-976. DOI: 10.1080/14728222.2017.1369961
    DOI del artículo: 10.1080/14728222.2017.1369961
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2017
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Clinical Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Pharmacology & Pharmacy
    Type-2 diabetes-mellitus
    Subclinical atheromatosis
    Risk-factors
    Peritoneal-dialysis
    Lipoproteins
    Lipid abnormalities
    High-density-lipoprotein
    Hemodialysis-patients
    Dyslipidemia
    Chronic-renal-failure
    Chronic kidney-disease
    Chronic kidney disease
    Cardiovascular-disease
    Cardiovascular disease
    Atherosclerosis
    dyslipidemia
    chronic kidney disease
    cardiovascular disease
    atherosclerosis
    Pharmacology & pharmacy
    Pharmacology
    Molecular medicine
    Medicina ii
    Medicina i
    Interdisciplinar
    Farmacia
    Ensino
    Drug discovery
    Clinical biochemistry
    Ciências biológicas iii
    Ciências biológicas ii
    Ciência de alimentos
  • Documentos:

  • Cerca a google

    Search to google scholar